30
Participants
Start Date
June 30, 2003
Primary Completion Date
February 29, 2012
Study Completion Date
February 29, 2012
bevacizumab
"Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.~Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose."
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles
Collaborators (1)
National Cancer Institute (NCI)
NIH
Genentech, Inc.
INDUSTRY
Jonsson Comprehensive Cancer Center
OTHER